Research Article

Colonic and Hepatic Modulation by Lipoic Acid and/or N-Acetylcysteine Supplementation in Mild Ulcerative Colitis Induced by Dextran Sodium Sulfate in Rats

Fabiana Andréa Moura,1,2 Kívia Queiroz de Andrade,2 Orlando Roberto Pimentel de Araújo,3 Valéria Nunes-Souza,4,5 Juliana Célia de Farias Santos,2 Luiza Antas Rabelo,2,4,6 and Marília Oliveira Fonseca Goulart3,6

1Faculdade de Nutrição (FANUT), Universidade Federal de Alagoas (UFAL), Campus A. C. Simões, Tabuleiro dos Martins, 57072-970 Maceió, AL, Brazil
2Pós-Graduação em Ciências da Saúde (PPGCS/UFAL), Maceió, AL, Brazil
3Instituto de Química e Biotecnologia (IQB/UFAL), Maceió, AL, Brazil
4Laboratório de Reatividade Cardiovascular (LRC/UFAL), Maceió, AL, Brazil
5Departamento de Fisiologia e Farmacologia (DFF), Centro de Biociências (CB), Universidade Federal de Pernambuco (UFPE), Av. Prof. Moraes Rego, 1235 Cidade Universitária, 50670-901 Recife, PE, Brazil
6Rede Nordeste de Biotecnologia (RENOBIO), Recife, PE, Brazil

Correspondence should be addressed to Marília Oliveira Fonseca Goulart; mariliaofg@gmail.com

Received 22 June 2016; Revised 3 October 2016; Accepted 10 October 2016

Academic Editor: Karina Reyes-Gordillo

Copyright © 2016 Fabiana Andréa Moura et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Lipoic acid (LA) and N-acetylcysteine (NAC) are antioxidant and anti-inflammatory agents that have not yet been tested on mild ulcerative colitis (UC). This study aims to evaluate the action of LA and/or NAC, on oxidative stress and inflammation markers in colonic and hepatic rat tissues with mild UC, induced by dextran sodium sulfate (DSS) (2% w/v). LA and/or NAC (100 mg kg⁻¹ day⁻¹, each) were given, once a day, in the diet, in a pretreatment phase (7 days) and during UC induction (5 days). Colitis induction was confirmed by histological and biochemical analyses (high performance liquid chromatography, spectrophotometry, and Multiplex®). A redox imbalance occurred before an immunological disruption in the colon. NAC led to a decrease in hydrogen peroxide (H₂O₂), malondialdehyde (MDA) levels, and myeloperoxidase activity. In the liver, DSS did not cause damage but treatments with both antioxidants were potentially harmful, with LA increasing MDA and LA + NAC increasing H₂O₂, tumor necrosis factor alpha, interferon gamma, and transaminases. In summary, NAC exhibited the highest colonic antioxidant and anti-inflammatory activity, while LA + NAC caused hepatic damage.

1. Introduction

The use of antioxidants is considered an important complementary therapy in several conditions such as cardiometabolic, neurological, and gastrointestinal (GI) diseases, for cancer prevention and others [1]. Among the GI disorders, inflammatory bowel diseases (IBD), composed of ulcerative colitis (UC) and Crohn’s disease (CD), affect 150–250/100,000 people, especially in the USA and Europe, with substantial health care costs of approximately US$6 billion and €4.6–5.6 billion, per year, respectively [2, 3].

Despite extensive research, the etiology of IBD has yet to be elucidated; however it is considered closely connected to genetic and immunologic factors, microbiota, and oxidative stress, which, in the case of UC, concerns both etiology and symptoms such as increase of intestinal permeability by destruction of tight junctions and increase of infection and inflammation by neutrophil infiltration. Hence, the presence
of colonic ulcers, as a consequence of lipid peroxidation and protein damage and development of cancer, is due to DNA damage [4]. However, the cause of these symptoms and clinical manifestations is heterogeneous, varying according to the UC level: mild, moderate, or severe. In humans, the most common and problematic stage of UC is mild colitis [5]. It is characterized by normal albumin, body temperature, pulse, and hematocrit ratio, associated with an erythrocyte sedimentation rate of <20 mm/h, less than 4 bowel movements per day and no weight loss [6]. Nevertheless, this classification may differ according to authors and adopted criteria [7, 8].

The extraintestinal manifestations of IBD, such as the systemic effects of alternative therapy used for IBD treatment, are poorly explored. Among these manifestations, emphasis is given to hepatobiliary disorders. The close relationship between the liver and intestine is justified by their common embryogenesis until later in adult life (intestine to portal vein) [9]. However, the main focus of the cited studies was microbiota, which has received special attention due to its intimate connection with metabolic syndrome, obesity, and nonalcoholic fatty liver diseases [10].

A pioneer study showed that, after colitis induction (4% of DSS for 7 days), important liver injury occurred, confirmed by higher serum levels of haptoglobin and various histological findings, such as signs of necrosis and ballooning of hepatocytes [11].

The use of antioxidants has emerged as an alternative therapy for IBD. Among them, lipoic acid (LA) and N-acetylcysteine (NAC) stand out, which have been tested separately in UC [4], and in combination for other clinical conditions [11, 12], with positive results.

Due to its antioxidant property in both forms, oxidized (LA) and reduced (dihydrolipoic acid, DHLA), LA is called a “universal antioxidant.” The LA/DHLA couple is a scavenger of superoxide anion radical (O$_2^−$), hypochlorous acid (HOCl), peroxynitrite (ONOO$^−$), and nitric oxide (NO). It is able to restore the exogenous antioxidants tocopherol and ascorbic acid and the endogenous antioxidant system of reduced/oxidized glutathione (GSH/GSSG) [6]. Additionally, in vitro studies suggest that LA acts as an inhibitor of IkB kinase-2 (IKK2), with subsequent release of nuclear factor kappa B (NF-kB) [13]. Another anti-inflammatory effect is the elevation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) intracellular levels that occurs through independent mechanisms, by breaking links between Nrf2 and Keap 1 (Kelch ECH associating protein 1). These actions lead to decreased expression of various proinflammatory cytokines and increased expression of enzymatic antioxidants, such as glutathione peroxidase (GPx) and superoxide dismutase (SOD) [14].

NAC is a strong reducing agent [15]. Like LA, NAC is an important scavenger of reactive molecules and plays a role as a metal chelator. However, the most important antioxidant action assigned to NAC is the increase in antioxidant defense activity by providing cysteine, which is required for GSH synthesis. The anti-inflammatory effects of NAC have also been confirmed, through observation of NF-kB inhibition [16].

Taking into consideration that LA and NAC, alone and in combination, were successfully tested in several systems and in regard the intimate bowel-liver association, the aim of this study was to evaluate the action of LA and/or NAC, on oxidative stress and inflammation in mild colitis induced by DSS.

2. Materials and Methods

2.1. Chemicals. DSS MW 36,000–40,000 Da is from MP Biomedicals. LiChrolut® RP-18 E is from Merck, cytokine kits are from Milliplex MAP Mouse Cytokine/Chemokine Panel (Merck Millipore®), protease inhibitor cocktail tablets are from Roche®, and RIPA buffer are from Cell Signaling®. LA and NAC from Ao Pharmaceutico (Alagoas/Brazil) and all other chemicals and enzymes from Sigma-Aldrich® Chemicals.

2.2. Equipment. HPLC coupled to UV detector (Shimadzu®), freezer VIP Series Sanyo, spectrofluorometer (ThermoScientific Multiskan), and an optic microscopy Olympus BX51 attached to a DP70 Digital Camera System and a MAGPIX® Multiplex Reader were used.

2.3. Animals. Experimental protocol was approved by the Institutional Animal Ethic Committee/Universidade Federal de Alagoas (IAEC/UFAL) (05/2014) and was performed in accordance with the Committee for the Purpose of Control and Supervision of Experimentation on Animals (CPCSEA) guidelines. Adult male Wistar rats, 185–203 g, were obtained from the Central Animal House of UFAL and kept in individual cages, under controlled conditions, at room temperature (22 ± 2°C), humidity (50 ± 10%), and light (12/12 h light/dark). Commercial feed (Nuvilab®) and water were provided ad libitum.

2.4. UC Induction and Experimental Design. Animals were divided into 5 groups. Healthy rats received commercial feed (control group). Mild UC was induced in four groups with 2% w/v DSS, administered in drinking water for 5 days. Antioxidants-treated rats were supplemented 7 days before mild colitis induction with lipoic acid (LA, 100 mg/kg/d), N-acetylcysteine (NAC, 100 mg/kg/d), or LA + NAC (100 mg/kg/d, each). Doses of the two antioxidants used are considered safe to rats/mice (LA up to 1800 mg/d [17] and NAC up to 6000 mg/d) and have been tested successfully in several physiological/pathophysiological conditions in mice/rats [16, 18].

2.5. Euthanasia, Blood Sample Collection, General Biochemical Profile, and Preparation of Tissue Homogenates. At the 13th day, after 12 h of fasting, the animals were anesthetized (ketamine, 100 mg/kg, and xylazine, 15 mg/kg, via i.p.), and blood was collected by cardiac puncture. After perfusion with heparin solution (1:50 v/v), aorta was sectioned. The organs were then, dissected, placed on liquid nitrogen, and immediately stored at −80°C. Tissue homogenates were prepared, within ice cold, with RIPA buffer with protease inhibitor cocktail (one tablet for 50 mL of RIPA buffer), and were
centrifuged at 19,600 × g/20 min, at 4°C. The supernatants were stored at −80°C.

Biochemical analyses were made by certified laboratory, using well-established methods. Colon and liver tissues were washed in saline and weighed. The left lobe of the liver and distal colon were cut, for use in histological analysis.

2.6. Histological Analysis. After fixation with 10% buffered formalin, the organs were cleaved and the sections were processed by embedding in paraffin and stained with hematoxylin and eosin (HE) to histological evaluation. Total collagen was evaluated by Masson trichrome staining kit. Briefly, one section of each, liver and bowel, was obtained and stained by using Masson's original trichrome stain, with collagen stained in blue, nuclei in purple-brown, and cytoplasm in pink. Collagen area was defined as the distinct blue color region and was distinguished from muscle, blood, and inflammatory cells. Afterwards, ImageJ software was used to quantify the blue area (pixel/cell).

2.7. Malondialdehyde (MDA), Hydrogen Peroxide (H2O2), and Nitrite Levels. MDA contents were measured by reverse phase ion pair HPLC, with UV detector at 270 nm, according to Tatum et al. [19]. HPLC system conditions were C18, ultra-science column 150 mm × 4.6 mm and 45 mm × 4.6 mm guard column, the mobile phase comprised acetonitrile HPLC/UV grade, and Trizma buffer (pH 7.4) (1:9). The intestinal or hepatic tissue was homogenized with Trizma buffer, BHT, and Trizma buffer (pH 7.4). Then, the homogenate was centrifuged at 872 × g/10 min, at 4°C, and the supernatant was filtrated with HPLC filter (0.22 mm). The flow rate was 1.0 mL-min⁻¹ and MDA was calculated from the standard curve, generated using 1,1,3,3-tetramethoxypropane and expressed as nmol MDA-mg tissue⁻¹. The retention time was around 2 min 40 s.

H2O2 was measured according to Pick and Keisari [20]. Hepatic or colonic tissues were homogenized in 1.0 mL of assay buffer containing 140 mM NaCl, 10 mM PBS, pH 7.0, and 5.5 mM dextrose. After centrifugation (2000 × g/5 min at 4°C), the supernatant was transferred to microtubes, containing 0.28 mM phenol red, 8.5 U/mL of horseradish peroxidase, and assay buffer. After incubation (37°C for 30 min), NaOH 1M was added. The samples were read at 610 nm. The concentration was expressed as nmol-mg protein⁻¹.

Nitrite assay was performed based on Griess method adapted for microplates. Supernatant was mixed with 2,3-diaminonaphthalene (50 μg·mL⁻¹ in 0.2 M HCl) and incubated at room temperature/10 min. The reaction was interrupted by the addition of NaOH (2.8 M) and monitored at 540 nm. The result was expressed as μmol-mg protein⁻¹.

2.8. Measurement of Enzyme Activity. SOD was measured following S. Marklund and G. Marklund [21]. Liver or colon supernatant was added to 0.2 mM pyrogallol (dissolved in 50 mM potassium phosphate buffer (PBS), pH 6.5) to initiate the reaction, and the decrease of the absorbance related to pyrogallol was monitored at 420 nm. One unit of SOD was defined as the amount required for inhibiting pyrogallol autoxidation by 50% per min. The result was expressed as U·mg protein⁻¹ [22]. CAT activity was measured as the rate of decomposition of H2O2, as described elsewhere [23], and was monitored at 540 nm. Relative activity was expressed as IU·min·mL·mg protein⁻¹.

Total GPx activity was measured according to Flohe and Gunzler [24], adapted to microplate. The hepatic or colonic tissue was homogenized with assay buffer (PBS 0.1 M, EDTA 5 mM, pH 7.4) and centrifuged (14,000 × g/20 min, at 4°C). Supernatant was added to wells (in duplicate), followed by the addition of glutathione reductase (GR) (0.048 U) and GSH (10 mM), incubated at 37°C/10 min and afterwards, nicotinamide adenine dinucleotide phosphate (NADPH) (1.5 mmol) and tert-butyl hydroperoxide (0.5 mM) were added. The decrease in the absorbance of the system was measured, for 5 min, at 340 nm. One unit of tGPx was defined as the amount of enzyme able to catalyze the oxidation of 1 μmol of NADPH to NADP⁺ in 1 min. The result was expressed as U·mg protein⁻¹.

MPO activity was measured according to Bradley et al. [25]. Hepatic or colonic tissue was homogenized using assay buffer pH 6.0 (PBS, 50 mM, 0.5% hexadecyltrimethylammonium bromide and EDTA, 5 mM) and centrifuged at 1550 × g/15 min (4°C). Supernatant was collected and centrifuged at 14,000 × g/15 min (4°C). The sample was transferred (duplicate) to microplate and ortho-dianisidine solution (0.8 mg/mL) was added. After incubation (37°C/15 min), a solution of H2O2 (0.3%) was added. A new incubation was performed (37°C/10 min) and the reading was made at 460 nm. One unit of MPO was defined as the quantity that decomposes 1 μmol of H2O2. The result was expressed as U·mg protein⁻¹.

2.9. Measurement of Total GSH. GSH and GSSG were measured according to Tripple and Rogers [26], with slight modifications. First, total protein was precipitated, after centrifugation (190 × g/10 min, at −20°C) with metaphosphoric acid (1:1). To obtain total GSH (tGSH), this supernatant was diluted in assay buffer (PBS 0.1 M, EDTA 5 mM, pH 7.4). Then, the homogenates were transferred to microplates, and the final volume (150 μL) was completed with assay buffer. Afterwards, the reaction was started, upon addition of Reaction Mixture 1 (containing 5,5′-dithiobis-(2-nitrobenzoic acid), DTNB, 10 mM, and GR, 4.2 U/mL) and NADPH, 1% w/v.

To measure GSSG, the supernatant was diluted (1:50) in assay buffer, containing N-ethylmaleimide (NEM), and centrifuged (10,000 × g/20 min at 4°C). This solution was incubated for 50 minutes to complete GSH complexation and removal. To exclude NEM, this supernatant with assay buffer were eluted through Sep-pak® Classic C18 cartridges. Afterwards, the eluent was transferred to microplate and Reaction Mixture 1 and NADPH,1% w/v, were added.

In both analyses, the absorbance was measured over 3 min at 412 nm with 30 s intervals. GSH was determined according to the following equation: GSH = tGSH − (GSSG/2). Results were expressed in nM·mg protein⁻¹.
2.10. TNF-α, IL-10, and Interferon Gamma (INFγ) Levels. Cytokine production was quantified by Milliplex MAP Mouse Cytokine/Chemokine Panel (Merck Millipore), following the manufacturer’s instruction. The results were expressed as pg mg protein^{-1}.

2.11. Statistical Analysis. Normality was assessed by the Kolmogorov-Smirnov test. Parametric variables were evaluated using the paired one-way analysis of variance (ANOVA), followed by Tukey’s or Bonferroni’s posttest. Student’s t-test was performed just to confirm the disease in Mild colitis group. The Kruskal-Wallis test was used for assessing the nonparametric variables and corresponding post hoc analysis. Results were shown as mean ± standard error (SEM) for those with normal distribution and as median values and interquartile range for the nonparametric ones. Two-sided p value <0.05 was considered statistically significant. GraphPad® Prism version 5.0 for Windows software (San Diego, CA, USA) was used.

3. Results

For the sake of clarity, results are divided into three topics: general, colonic, and hepatic results.

3.1. General Results

3.1.1. Mild Colitis and Supplementation Did Not Alter Body Weight, Food Intake, or Liver and Colon Weights. In both phases (PT and T) of the study, DSS or supplementation by antioxidants did not induce effects on body weight or food intake patterns compared to the control group (Figures 1(a) and 1(b)). Similarly, body weight was unchanged over the evaluation period (Figure 1(c)). Absolute and relative liver and colon weights were unchanged (Table 1). Water ingestion modification was also not observed (data not shown).

3.1.2. LA and NAC, but Not LA + NAC, Decreased Anemia and Leukocytosis Caused by Mild Colitis. Anemia in the mild colitis group was confirmed by a decrease in red blood cells (RBC) and hemoglobin (HB) (Figures 2(a) and 2(b)), since clinical changes such as rectal blood, diarrhea, and weight loss were not observed or did not show differences between the groups. No macroscopic change was observed after euthanasia (data not shown). All treatments increased the parameters (RBC, HB). However, LA and NAC alone ameliorated the typical UC inflammation, represented by a decrease in leukocytes, while the combination of LA + NAC did not show beneficial effects (Figure 2(c)).

3.1.3. LA + NAC Increased Levels of Aminotransferases. The use of DSS and NAC did not cause a change in the available serological biomarkers, unlike LA supplementation, which promoted a decrease of globulin levels versus the mild colitis group (p < 0.01). However, this biochemical alteration did not exhibit physiological relevance, since albumin, the most important biomarker of hepatic function, remained statistically unaltered among the groups (Table 2). Moreover, it is important to observe that the combined action of LA and NAC on biomarkers of hepatic injury differed from the control (p < 0.05) and NAC (p < 0.05) groups. Compared to the NAC group, ALT and AST in the LA + NAC group were 2.2x and 2x higher, respectively. Despite the fact that these enzymes are not exclusive markers of liver damage, their increase in clinical situations such as heart disease and myopathies, when analyzed together with oxidative (Figure 7) and inflammatory (Figure 8) parameters, may be considered as a disruption of the liver metabolism balance. The other systemic biomarkers analyzed were not seen to be statistically significant.

3.2. Colonic Results

3.2.1. LA or NAC Reduced Histological Damage on the Colon Induced by DSS. Samples from DSS-treated animals (mild colitis) showed higher histological damage (Figure 3(a)) than other groups. Although all the treated groups showed these changes, damage to the mucosal architecture was reduced when antioxidants were used, showing a protective effect of the antioxidants, when compared to the mild colitis group. Collagen deposition (Figure 3(b)), marked with a blue color, confirms the presence of fibrotic tissue in mild colitis (Figure 3(b)). LA and/or NAC treatments were able to decrease this deposition but were not sufficient to prevent mild UC lesions and their collagen counts were equal to the mild colitis and control groups (p > 0.05) (Figure 3(c)).

3.2.2. Colonic Oxidative Damage Is the First Signal Observed in Mild Colitis. Oxidative damage represented by increased H₂O₂ (Figure 4(a)), nitrite (Figure 4(b)), and MDA (Figure 4(c)) levels, together with a decrease in CAT activity (Figure 4(d)), was already present in the mild colitis group and confirms the involvement of oxidative stress in the pathogenesis of UC. NAC was able to restore both H₂O₂ and MDA to levels equal to the control group and decreased MPO levels versus the mild Colitis group (p < 0.05), thereby confirming its higher antioxidant power relative to LA. Interestingly, NAC decreased SOD activity (Figure 4(e)) compared to the LA group. At the same time, it decreased

| Tissue/Ratio | Control | Mild colitis | LA | NAC | LA + NAC |
|-------------|---------|-------------|----|-----|----------|
| Colon (g)   | 2.54 ± 0.10 | 2.30 ± 0.14 | 2.21 ± 0.11 | 2.19 ± 0.15 | 2.02 ± 0.10 |
| Colon/body weight ratios | 0.01 ± 0.00 | 0.01 ± 0.00 | 0.01 ± 0.00 | 0.01 ± 0.00 | 0.01 ± 0.00 |
| Liver (g)   | 8.74 ± 0.40 | 8.76 ± 0.28 | 8.57 ± 0.31 | 8.22 ± 0.39 | 8.40 ± 0.14 |
| Liver/body weight ratios | 0.04 ± 0.00 | 0.04 ± 0.00 | 0.04 ± 0.00 | 0.04 ± 0.00 | 0.04 ± 0.00 |
colonic oxidative damage. In mild colitis, NAC activity may be maintained due to an increase in GSH (Figure 4(g)) and consequently GSSG (Figure 4(h)), as a response attempt of the body to oxidative damage. There were no alterations in the GSH/GSSG ratio (Figure 4(i)) and GPx levels for all groups (Figure 4(j)).

3.2.3. Changes in Intestinal Cytokines Were Not Observed in Mild UC and LA + NAC Provoked Inflammation. Colonic inflammation represented by proinflammatory cytokines TNF-α and INF-γ, involved in innate immunity, and the anti-inflammatory cytokine IL-10, was not altered in the mild colitis group, compared to the control (Figures 5(a), 5(b), and 5(c)). However, LA + NAC promoted an increase in TNF-α (versus control, LA, and NAC groups) (Figure 5(a)) and IL-10 (versus all groups) (Figure 5(c)). Probably IL-10 increased to minimize the proinflammatory effects caused by TNF-α.

3.3. Hepatic Results

3.3.1. Mild Colitis, LA, and/or NAC Did Not Cause Histological Alterations in the Liver. Biochemical and histological analyses (Table 2) suggest an absence of hepatic injury caused by DSS. However, despite the fact that the association between LA and NAC indicated concerning effects on this tissue, which can be observed by an increase in ALT and AST levels, only one morphological alteration could be identified: a periportal zone with disorganized hepatocyte cords (Figure 6(a)) without a necrosis area or collagen deposition (Figures 6(b) and 6(c)).

3.3.2. LA and/or NAC Present Different Redox Modulations. DSS did not cause hepatic redox imbalance. NAC exhibited an improved SOD effect (increase) versus the LA group (Figure 7(a)), while LA increased CAT (versus
Figure 2: Red blood cells (RBC) (10⁶ cells·μL⁻¹) (a); hemoglobin (g·dL⁻¹) (b); and leukocytes (10³ cells·μL⁻¹) (c), according to group (control; mild colitis; lipoic acid, LA; N-acetylcysteine, NAC; LA associated with NAC – LA + NAC). *P < 0.05 (Tukey test).

NAC) (Figure 7(f)), GSH (versus mild colitis and NAC) (Figure 7(g)), and consequently GPx (versus control) (Figure 7(j)). These results confirm that different antioxidants act on redox imbalance via different pathways. However, as observed by biochemical analysis, LA + NAC acted as a prooxidant supplement, causing an increase in H₂O₂ (Figure 7(b)).

3.3.3. LA + NAC Caused Inflammation in the Liver. In the liver, the levels of cytokines were not modified in the mild colitis group compared to the control group (Figures 8(a), 8(b), and 8(c)). However, it is important to notice, in both tissues (colon and liver), the proinflammatory effects of LA associated with NAC (LA + NAC). In hepatic tissue, this combination provoked the increase of TNF-α and INF-γ levels, when compared to all groups (Figures 8(a) and 8(b)).

4. Discussion
Analyses of histology, oxidative stress, and inflammatory biomarkers were performed on colonic and liver tissues, in order to investigate the role of added antioxidants (NAC and/or LA) in controlling damage caused by DSS. In this context, we observed that redox imbalance was the first alteration in mild colitis; NAC was able to reduce oxidative stress and cell damage, DSS (2% w/w) did not cause hepatic modification, and LA + NAC increased inflammation in the colon and liver.

4.1. Colonic Injury and the Effects of Supplementation. Previous studies have provided compelling evidence for the association between DSS and different degrees of UC [27, 28], from mild colitis up to carcinogenesis, according to its continuous administration, at 2–5% w/v, for a short period of time (4–9 days). Moreover, histological, biochemical, and immunological alterations caused by DSS are similar to UC in humans [29]. The exact mechanism of colitis induction by DSS is not known, but it seems to involve dysfunctional macrophages, luminal bacterial alterations, and direct toxicity to epithelium [30].

The redox profile was the first biochemical parameter to be altered, before immunological changes, particularly in
Figure 3: Hematoxylin and eosin staining (a) 50x magnification: arrows show the colonic lesions with neutrophil infiltration in mucosa and crypts' destruction; Masson trichrome staining (b) 100x magnification: the blue color shows areas with accumulation of mucous and collagen, especially on the lamina itself, submucoosa, and between crypts. (c) Colonic collagen counts confirm fibrosis in the mild colitis group (control; mild colitis; Lipoic acid, LA; N-acetylcysteine, NAC; LA associated with NAC – LA + NAC). * $p < 0.05$ (Dunn’s test).
Figure 4: Continued.
Figure 4: Colonic oxidative markers: hydrogen peroxide (H$_2$O$_2$) levels (a); nitrite levels (b); malondialdehyde (MDA) levels (c); catalase activity (d); myeloperoxidase (MPO) activity (e); superoxide dismutase (SOD) activity (f); reduced glutathione (GSH) levels (g); oxidized glutathione (GSSG) levels (h); GSH/GSSG ratio (i); and glutathione peroxidase (GPx) activity (j), according to group: control; mild colitis; lipoic acid, LA; N-acetylcysteine, NAC; LA associated with NAC – LA+NAC.

Table 2: Biochemical plasma analysis (mean ± SEM), according to group: control; mild colitis; lipoic acid, LA; N-acetylcysteine, NAC; LA associated with NAC – LA+NAC.

|            | Control          | Mild colitis     | LA              | NAC              | LA+NAC         |
|------------|------------------|------------------|------------------|------------------|----------------|
| HbA1c (%)  | 7.80 ± 0.15      | 7.97 ± 0.29      | 8.50 ± 0.40      | 8.13 ± 0.33      | 7.88 ± 0.28    |
| Glucose (mg/dL) | 189.0 ± 31.35 | 207.8 ± 38.77   | 196.0 ± 61.01    | 156.2 ± 23.66    | 176.4 ± 18.76  |
| CRP (mg/dL)       | 2.22 ± 0.32      | 2.20 ± 0.16      | 1.90 ± 0.25      | 2.15 ± 0.30      | 2.18 ± 0.29    |
| Calcium (mg/dL)   | 9.25 ± 0.31      | 8.90 ± 0.29      | 8.13 ± 0.90      | 8.68 ± 0.23      | 8.64 ± 0.41    |
| TC (mg/dL)        | 76.00 ± 7.69     | 65.75 ± 7.20     | 70.50 ± 5.50     | 72.25 ± 5.45     | 64.33 ± 8.67   |
| TG (mg/dL)        | 55.50 ± 14.56    | 63.25 ± 14.48    | 53.50 ± 0.71     | 54.25 ± 7.01     | 50.20 ± 19.83  |
| LDL-C (mg/dL)     | 37.56 ± 14.37    | 30.32 ± 5.67     | 31.80 ± 3.60     | 35.90 ± 5.37     | 29.96 ± 5.70   |
| HDL-C (mg/dL)     | 27.33 ± 2.26     | 24.50 ± 1.76     | 28.00 ± 2.00     | 25.50 ± 0.87     | 23.60 ± 3.17   |
| AST (U/L)         | 167.50 ± 27.91   | 194.00 ± 20.72   | 297.75 ± 59.74   | 153.40 ± 20.34   | 359.75 ± 76.95ad |
| ALT (U/L)         | 82.83 ± 5.83     | 104.25 ± 6.14    | 133.00 ± 24.78   | 85.25 ± 6.02     | 168.25 ± 38.60ad |
| AP (U/L)          | 420.50 ± 33.84   | 345.00 ± 12.45   | 315.00 ± 66.24   | 302.40 ± 46.64   | 305.00 ± 53.97 |
| TB (mg/dL)        | 0.12 ± 0.00      | 0.10 ± 0.02      | 0.10 ± 0.02      | 0.12 ± 0.01      | 0.10 ± 0.02    |
| DB (mg/dL)        | 0.03 ± 0.00      | 0.02 ± 0.00      | 0.03 ± 0.00      | 0.02 ± 0.00      | 0.03 ± 0.00    |
| IB (mg/dL)        | 0.10 ± 0.00      | 0.07 ± 0.02      | 0.08 ± 0.00      | 0.09 ± 0.01      | 0.08 ± 0.01    |
| TP (g/dL)         | 5.24 ± 0.19      | 4.63 ± 0.48      | 4.20 ± 0.41      | 4.78 ± 0.17      | 4.66 ± 0.14    |
| ALB (g/dL)        | 2.90 ± 0.27      | 2.28 ± 0.89      | 2.50 ± 0.46      | 2.74 ± 0.18      | 2.68 ± 0.15    |
| GLOB (g/dL)       | 2.30 ± 0.09      | 1.95 ± 0.03      | 1.70 ± 0.15as    | 2.04 ± 0.10      | 1.98 ± 0.10    |

HbA1c = glycosylated hemoglobin; CRP = C reactive protein; TC = total cholesterol; TG = triacylglycerol; LDL-C = low-density lipoprotein; HDL-C = high density lipoprotein; AST = aspartate aminotransferase; ALT = alanine aminotransferase; AP = alkaline phosphatase; TB = total bilirubin; DB = direct bilirubin; IB = indirect bilirubin; TP = total protein; ALB = albumin; GLOB = globulin; $^a$P < 0.05 versus control; $^{ad}P < 0.01$ versus control; $^b$P < 0.05 versus NAC (Tukey test). $^\Psi$ Kruskal-Wallis and Dunn’s test.

virtue of increased H$_2$O$_2$ and nitrite levels. Colonic injury typical of UC, represented by destruction of crypts and disorganization of intestinal structure, was observed in all groups that received DSS. Similar results were reported by other authors [31, 32]. However, LA and/or NAC supplementation could not prevent this damage, including collagen deposition (Figures 3(b) and 3(c)).

Even alone, LA has shown to exhibit negative effects in human studies. Wray et al. analyzing cardiovascular risk in elderly people observed that 600 mg/d of LA + Vit C (1000 mg) and Vit E (600 IU), 3x per week for 6 weeks, nullified positive effects on blood pressure, caused by exercise [33]. Additionally, McNeilly et al. [34], studying cardiovascular risk in obese patients with glucose intolerance, tested 1g/d of LA for 12 weeks, with or without exercise, and detected no improvement on serum lipid profile and increased oxLDL. Showkat et al. [35] tested LA (600 mg), 30 minutes prior to iron administration in patients with chronic renal failure on hemodialysis, and observed an increase in F2 isoprostanes and lipid hydroperoxide,
b biomarkers of lipid peroxidation, thereby confirming cell disruption.

LA was able to scavenge $H_2O_2$ and decrease LP (MDA levels), but NAC was more effective, completely preventing the increase of these markers. NAC was also shown to be effective in chronic UC, induced by DSS (5% w/v for 5 days), as observed by Amrouche-Mekkioui and Djerdjouri [28]. According to these authors, NAC (150 mg·kg$^{-1}$·d$^{-1}$ for 45 days) decreased colitis symptoms, inflammation, cell apoptosis, and MPO and $NO$ levels. Collectively, these results indicate the antioxidant and anti-inflammatory effects of NAC at different stages of UC.

$NO$ is a reactive molecule associated with UC progression, especially regarding toxic megacolon. In addition, $NO$ reacts with $O_2^-$, forming peroxynitrite, which causes LP and consequent ulcers in the colon mucosa. Both lesions are common in IBD [4]. $NO$ production is catalyzed by the enzyme nitric oxide synthase (NOS). In inflamed tissue, such as the colon in UC, the inducible isoform of the enzyme (iNOS) is highly expressed in DSS-inflamed colons and the colon of UC patients [36]. This enzyme, present in its own colonocyte, may be responsible for the increase of nitrite levels in the mild colitis group.

$F_2$-isoprostane is the best general indicator of nonenzymatic lipid peroxidation in complex biological systems [37]. However, in a recent systematic review on antioxidant therapy published by our group, we observed that the majority of the studies used MDA (identified directly by HPLC, or indirectly by thiobarbituric acid reactive substances, TBARS) to measure LP. In our study, a MDA assay was chosen.

In the present study, alterations in colonic SOD and GPx (Figures 4(f) and 4(j)) in the mild colitis group were not observed, which is similar to data reported by Akman et al. [38], who studied patients with active intestinal inflammation. On the other hand, the lower SOD activity observed in the NAC versus LA group, without evidence of increased
H$_2$O$_2$ levels, confirms the major antioxidant power of NAC in our model.

Recently, antioxidant therapy for IBD has gained increased recognition [4]. However, SOD activity has been poorly investigated regarding LA and NAC administration, probably because SOD is an enzyme whose activity is modestly reduced, during tissue inflammation, unlike GPx2, a gastrointestinal-specific form of GPx [36], which is closely associated with H$_2$O$_2$ metabolism, and whose gene expression is downregulated in several experimental models of UC [39].

Our findings on elevated GSH and GSSG levels in the mild colitis group are different from the findings of Amrouche-Mekkioui and Djerdjouri [28]. This increase may
Figure 7: Continued.
be explained by the role played by GSH in inhibiting apoptosis signaling not only by scavenging intracellular ROS but also by inhibiting cytochrome c release from mitochondria and regulating the activity of redox-sensitive caspases [40]. In our results, the influence of oxidative stress on GSH cycling was confirmed by an increase of GSSG. However, the concomitant elevation of GSH levels did not cause a change in the GSH/GSSG ratio, the most important biomarker.

The GI tract is a major site for generation of prooxidants, whose production is primarily due to the presence of a plethora of microbes, food ingredients, and interactions between immune cells [15]. The enhanced production of reactive species is associated with chronic intestinal inflammation in the early stages of IBD. Their destructive effects on DNA, proteins, and lipids may contribute to initiation and progression of UC, causing several symptoms, such as loss of blood and anemia, carcinogenesis, hepatotoxicity, nephrotoxicity, and hypersensitivity [41]. Besides that, oxidative stress increases inflammation and stimulates activation of NF-kB, with consequent production of proinflammatory cytokines, chemokines, growth factors, and adhesion molecules, which cause inflammation and fibrosis, identified in our study by the increase of leukocyte levels and collagen deposition.

TNF-α has been shown to play a critical role in the pathogenesis of IBD and biological therapy with TNF-α-blockers has been used as a mainstream treatment for downregulating aberrant immune responses and inflammatory cascades [42]. Additionally, INF-γ is involved with overexpression of several chemokines, such as IFN-γ-inducible protein 10 and IFN-γ-inducible T-cell α chemoattractant, in the intestinal mucosa for colitis induced in mice, and in UC patients [43]. On the other hand, IL-10, an anti-inflammatory cytokine, is required for regulating immune functions by promoting the widespread suppression of immune responses through its pleiotropic effects [44]. Imbalance in the production of these cytokines, such as TNF-α, plays a pivotal role in the signaling cascade of inflammatory pathways.

Guijarro et al. [45] in studying the effect of NAC plus mesalamine in UC patients also observed no changes in TNF-α plasma levels. It is possible that alterations were not identified because the model used in this study is for mild UC and upregulation of proinflammatory cytokines, such as IFN-γ and TNF-α, was observed more consistently in severe inflammation, such as colitis associated with carcinogenesis.

Unexpectedly, LA + NAC did not promote a beneficial action, even in increasing colonic IL-10 levels, which may be explained by the increase of leukocytes and dendritic cells, the latter responsible for its secretion and that are increased in colonic infiltrates [46]. IL-10 elevation has an anti-inflammatory response, especially in Th2 (T helper 2 lymphocytes) [47], related to autoimmune disorders such as UC [48]. In contrast to other studies [49, 50], a colonic increase of proinflammatory cytokines (Figures 5(a), 5(b), and 5(c)), despite the increase of leukocytes (Figure 2(c)), was not observed in the present study.

4.2. Hepatic Injury and the Effects of Supplementation. The extraintestinal manifestations of IBD are poorly explored by the scientific community. However, recent results have associated these manifestations to IBD activity [51] and the use of TNF-α inhibitors [52], exemplified by hepatobiliary manifestations, in terms of frequency and severity [53–55]. At the same time, these IBD complications remain underdiagnosed [56].

Despite the intimate connection between liver and colon, the oxidative and inflammatory alterations found in our model of mild colitis (2% of DSS, v/v, for 5 days) could have been insufficient to cause liver damage, unlike the results of Trivedi and Jena [57] and Farombi et al. [58]. However, when histological (Figure 6(a)), serological (Table 2), oxidative (Figure 7), and inflammatory (Figure 8) parameters were
Figure 8: Hepatic inflammatory markers: tumor necrosis factor alpha (TNF-α) (a), interferon gamma (INF-γ) (b), and interleukin 10 (IL-10) (c) levels according to group: control; mild colitis; lipoic acid, LA; N-acetylcysteine, NAC; LA associated with NAC – LA + NAC. *p < 0.05, **p < 0.01 (Tukey test).

evaluated, hepatic damage in the LA + NAC group was identified.

Unlike hepatic \( ^{\cdot}\)NO (Figure 7(d)), \( \text{H}_2\text{O}_2 \) production was seen to be stimulated by the combination of LA + NAC (Figure 7(f)), while no modification in histology and collagen depositions was observed in this group.

Mitochondria and redox-active enzymes can generate \( \text{O}_2^{\cdot^-} \) and \( \text{H}_2\text{O}_2 \) as byproducts in liver cells and these reactive molecules are increased under different conditions of chronic liver injury, caused by alcohol, xenobiotics, viral infections, nonalcoholic fatty liver disease, and others. Additionally, high concentrations of oxidative species, such as \( \text{H}_2\text{O}_2 \) and \( \cdot\)OH, induce hepatic stellate cell death and cause reduction of collagen deposition [59], which would explain the absence of changes in collagen deposition despite the higher levels of ALT and AST found in the serum of the LA + NAC group. Hepatic injury, whether acute or chronic, eventually results in an increase of serum concentrations of aminotransferases [60], suggesting stronger harmful action on the liver tissue, caused by the combination of these two antioxidants.

NAC supplementation led to an increase in hepatic SOD but without increasing \( \text{H}_2\text{O}_2 \) levels (versus mild colitis and LA), that is, improved redox status by activation of the antioxidant defense system. On the contrary, LA significantly increased CAT, GSH, and GPx, possibly due to increased oxidative stress observed in this group and confirmed by an elevation of MDA. Oxidative stress may be observed by GSSG levels, and although without statistical significance, these levels were approximately 61% higher than in the NAC group (Figure 7(i)).

Relative to lower CAT and GSH levels observed in the NAC group, these levels could be justified by the shorter period of supplementation. NAC protection against oxidative stress occurs by directing cysteine into the GSH synthesis pathway, with a consequent increase on the intracellular GSH content [16].

In a recent review, the authors showed that LA is generally administered associated with other substances and that this multiple therapy impairs the identification of the specific role of each component, raising difficulties in attributing
LA (100 mg·kg⁻¹) and/or NAC (100 mg·kg⁻¹) once a day - 12 days

DSS - 2% (v/v) - 5 last days

Liver Systemic Colon

DSS No alterations ↑ leukocytes; ↓ RBC, HB
LA ↑ MDA, CAT, GPx, GSH No alterations  No alterations
NAC ↑ SOD No alterations  ↓ MDA, MPO, SOD, H₂O₂
LA + NAC ↑ SOD No alterations  ↑ MDA, MPO, SOD, H₂O₂

Figure 9: ↑ = increased; ↓ = decreased; ALT = alanine aminotransferase; AST = aspartate aminotransferase; CAT = catalase; d = day; DSS = dextran sodium sulfate; GSH = glutathione reduced; GSSG = glutathione oxidized; H₂O₂ = hydrogen peroxide; HB = hemoglobin; IL = Interleukin; INFγ = interferon gamma; LA = lipoic acid; MDA = malondialdehyde; MPO = myeloperoxidase; NAC = N-acetylcysteine; RBC = red blood cells; SOD = superoxide dismutase; TNF-α = tumor necrosis factor alpha.

beneficial, synergistic, or antagonistic effects [18]. In this context, El-Gowelli et al., also using an animal model, observed that LA plus cyclosporine, an immunosuppressant used routinely in UC treatment, aggravates colon damage. Pop-Busui et al. studying patients with type 1 diabetes observed similar noxious effects in diabetic patients, using LA plus allopurinol (xanthine oxidase inhibitor) and nicotinamide whose combination did not prevent the progression of cardiovascular autonomic neuropathy.

It is important to emphasize that the LA + NAC group received 200 mg·kg⁻¹ (100 mg·kg⁻¹ of each antioxidant), an amount much lower than the maximum limit established for safety in the oral delivery of LA (10x less) [61] and NAC (30x less) [62]. Taken together, these results cast doubt on the concept of the “universal antioxidant” given to LA.

5. Conclusions

In our study, oxidative stress was the first biochemical manifestation of mild UC and happened before an increase in TNF-α and INF-γ. Additionally, NAC exhibits better antioxidant effects, especially regarding MDA and H₂O₂ levels. LA, administered daily, as a single dose increased hepatic MDA. LA + NAC increased oxidative and inflammatory profiles in the colon and liver (Figure 9).

In summary, our work provides evidence that the antioxidant and anti-inflammatory power of NAC involves not only the colon but also the liver. This fact confirms, for UC, the necessity to broaden the investigation to the liver, which is intimately connected to the colon.

The management of UC with alternative therapies is a large field of investigation and experimental colitis must mimic the human disease spectra. As presently shown, investigation on several tissues and organs is necessary, before a definite choice of a treatment can be made.

Abbreviation List

ALB: Albumin
ALT: Alanine aminotransferase
ANOVA: One-way analysis of variance
AP: Alkaline phosphatase
AST: Aspartate aminotransferase
BHT: Butylated hydroxytoluene
CAT: Catalase
cD: Crohn’s disease
CRP: C reactive protein
d: Day
DB: Direct bilirubin
DHLA: Dihydrolipoic acid
DNA: Deoxyribonucleic acid
DSS: Dextran sodium sulfate
DTNB: 5,5'-Dithiobis-2-nitrobenzoic acid
GI: Gastrointestinal
GLOB: Globulin
GPx: Glutathione peroxidase
GR: Glutathione reductase
GSH: Glutathione reduced
GSSG: Glutathione oxidized
H₂O₂: Hydrogen peroxide
HB: Hemoglobin
HbA1c: Glycosylated hemoglobin
HDL-C: High-density lipoprotein
HE: Hematoxylin and eosin
Additional Points

**Highlights.** Oxidative stress occurs before inflammatory alterations in mild colitis. **N**-Acetyl cysteine is a promising antioxidant toward alleviating ulcerative colitis. Lipoic acid and **N**-acetylcysteine improved oxidative biomarkers for colonic disease. The combination of lipoic acid and **N**-acetylcysteine causes important hepatic injury and colonic inflammation. Antagonist effects of antioxidants have been proven, when administered together in mild colitis.

**Competing Interests**

The authors confirm that this article's content has no conflict of interests.

**Acknowledgments**

The authors are grateful to Professor Dr. Emíliano Barreto and Professor Dr. Salete Smaniotto (Laboratório de Biologia Celular/ICBS/UFAL) and their M.Sc. and Ph.D. students for the contributions to histological and Milliplex MAP Mouse Cytokine/Chemokine Panel (Merck Millipore) analyses. Professor Dr. Antonio Euzébio Goulart Santana is also thanked for the experimental facilities provided. This work was supported by grants from the CNpq (4840044/2011-3, 407963/2013-8, and 458114/2014-6), PRONEX/FAPEAL/CNPq/2009-09-006, and PROCAD/CAPES/3004-2014.

**References**

[1] E. Ginter, V. Simko, and V. Panakova, “Antioxidants in health and disease,” Bratislava Medical Journal, vol. 115, no. 10, pp. 603–606, 2014.

[2] T. A. Malik, “Inflammatory bowel disease: historical perspective, epidemiology, and risk factors,” Surgical Clinics of North America, vol. 95, no. 6, pp. 1105–1122, 2015.

[3] G. G. Kaplan, “The global burden of IBD: from 2015 to 2025,” Nature Reviews Gastroenterology & Hepatology, vol. 12, no. 12, pp. 720–727, 2015.

[4] F. A. Moura, K. Q. de Andrade, J. C. F. dos Santos, O. R. P. Araújo, and M. O. F. Goulart, “Antioxidant therapy for treatment of inflammatory bowel disease: does it work?” Redox Biology, vol. 6, pp. 617–639, 2015.

[5] B. Siegmund, “Management of mild-to-moderate ulcerative colitis,” Digestive Diseases, vol. 33, supplement 1, pp. 90–94, 2015.

[6] R. C. Langan, P. B. Gotsch, M. A. Krafczyk, and D. D. Skillinge, “Ulcerative colitis: diagnosis and treatment,” American Family Physician, vol. 76, no. 9, pp. 1323–1330, 2007.

[7] A. Dignass, R. Elaikim, F. Magro et al., “Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part I: definitions and diagnosis,” Revista de Gastroenterologia de Mexico, vol. 79, no. 4, pp. 263–289, 2014 (Spanish).

[8] S. C. Truelove and L. J. Witts, “Cortisone in ulcerative colitis; final report on a therapeutic trial,” British Medical Journal, vol. 2, no. 4947, pp. 1041–1048, 1955.

[9] A. Wieland, D. N. Frank, B. Harnke, and K. Bambha, “Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease,” Alimentary Pharmacology and Therapeutics, vol. 42, no. 9, pp. 1051–1063, 2015.

[10] A. Abdul-Hai, A. Abdallah, and S. D. H. Malnick, “Influence of gut bacteria on development and progression of non-alcoholic fatty liver disease,” World Journal of Hepatology, vol. 7, no. 12, pp. 1679–1684, 2015.

[11] K. Jana, A. Dutta, P. Chakraborty et al., “Alpha-lipoic acid and N-acetylcysteine protects intensive swimming exercise-mediated germ-cell depletion, pro-oxidant generation, and alteration of steroidogenesis in rat testis,” Molecular Reproduction and Development, vol. 81, no. 9, pp. 833–850, 2014.

[12] I. G. Thakurta, M. Chattopadhyay, A. Ghosh, and S. Chakrabarti, “Dietary supplementation with N-acetyl cysteine, α-tocopherol and α-lipoic acid reduces the extent of oxidative stress and proinflammatory state in aged rat brain,” Biogerontology, vol. 13, no. 5, pp. 479–488, 2012.

[13] Z. Ying, T. Kampfrath, Q. Sun, S. Parthasarathy, and S. Rajagopalan, “Evidence that α-lipoic acid inhibits NF-κB activation independent of its antioxidant function,” Inflammation Research, vol. 60, no. 3, pp. 219–225, 2011.

[14] K. P. Shay, A. J. Michels, W. Li, A.-N. T. Kong, and T. M. Hagen, “Cap-independent Nrf2 translation is part of a lipoic
acid-stimulated detoxification stress response,” *Biochimica et Biophysica Acta*, vol. 1823, no. 6, pp. 1102–1109, 2012.

[15] A. M. Sadowska, B. Manuel-y-Keenoy, and W. A. De Backer, “Antioxidant and anti-inflammatory efficacy of NAC in the treatment of COPD: discordant in vitro and in vivo dose-effects: a review,” *Pulmonary Pharmacology and Therapeutics*, vol. 20, no. 1, pp. 9–22, 2007.

[16] K. Q. de Andrade, F. A. Moura, J. M. dos Santos, O. R. P. de Araújo, J. C. D. F. Santos, and M. O. F. Goulart, “Oxidative stress and inflammation in hepatic diseases: therapeutic possibilities of N-acetylcysteine,” *International Journal of Molecular Sciences*, vol. 16, no. 12, pp. 30269–30308, 2015.

[17] K. P. Shay, R. F. Moreau, E. J. Smith, A. R. Smith, and T. M. Hagen, “Alpha-lipoic acid as a dietary supplement: molecular mechanisms and therapeutic potential,” *Biochimica et Biophysica Acta* (BBA)—*General Subjects*, vol. 1790, no. 10, pp. 1149–1160, 2009.

[18] F. A. Moura, K. Q. de Andrade, J. C. F. dos Santos, and M. O. F. Goulart, “Lipoic acid: its antioxidant and anti-inflammatory role and clinical applications,” *Current Topics in Medicinal Chemistry*, vol. 15, no. 5, pp. 458–483, 2015.

[19] V. L. Tatcum, C. Changchit, and C. K. Chow, “Measurement of malondialdehyde by high performance liquid chromatography with fluorescence detection,” *Lipids*, vol. 25, no. 4, pp. 226–229, 1990.

[20] E. Pick and Y. Keisari, “A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture,” *Journal of Immunological Methods*, vol. 38, no. 1-2, pp. 161–170, 1980.

[21] S. Marklund and G. Marklund, “Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase,” *European Journal of Biochemistry*/*FEBS*, vol. 47, no. 3, pp. 469–474, 1974.

[22] M. M. Bradford, “A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding,” *Analytical Biochemistry*, vol. 72, no. 1-2, pp. 248–254, 1976.

[23] P. Xu, A. C. Costa-Goncalves, M. Todiras et al., “Endothelial dysfunction and elevated blood pressure in Mas gene-deleted mice,” *Hypertension*, vol. 51, no. 2, pp. 574–580, 2008.

[24] L. Flohe and W. A. Gunzler, “Assays of glutathione peroxidase,” *Methods in Enzymology*, vol. 105, pp. 114–121, 1984.

[25] P. P. Bradley, R. D. Christensen, and G. Rothstein, “Cellular and extracellular myeloperoxidase in pyogenic inflammation,” *Blood*, vol. 60, no. 3, pp. 618–622, 1982.

[26] T. E. Tipple and L. K. Rogers, “Methods for the determination of plasma or tissue glutathione levels,” *Methods in Molecular Biology*, vol. 889, pp. 315–324, 2012.

[27] N. Amini-Shirazi, A. Hoseini, A. Ranjarb et al., “Inhibition of tumor necrosis factor and nitrosative/oxidative stresses by *Ziziphus clinopoides* (Kahlilii); a molecular mechanism of protection against dextran sodium sulfate-induced colitis in mice,” *Toxicology Mechanisms and Methods*, vol. 19, no. 2, pp. 183–189, 2009.

[28] I. Amrouche-Mekkoui and B. Djerdjouri, “N-acetylcysteine improves redox status, mitochondrial dysfunction, mucin-depleted crypts and epithelial hyperplasia in dextran sulfate sodium-induced oxidative colitis in mice,” *European Journal of Pharmacology*, vol. 691, no. 1-3, pp. 209–217, 2012.

[29] M. Perie and A. Cerar, “Dextran sodium sulphate colitis mouse model: traps and tricks,” *Journal of Biomedicine & Biotechnology*, vol. 2012, Article ID 718617, 15 pages, 2012.

[30] I. Okayasu, S. Hatakeyama, M. Yamada, T. Ohkusa, Y. Inagaki, and R. Nakaya, “A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice,” *Gastroenterology*, vol. 98, no. 3, pp. 694–702, 1990.

[31] A. K. Pandurangan, S. Ismail, Z. Saadatdoust, and N. M. Esa, “Allicin alleviates dextran sodium sulfate- (DSS-) induced ulcerative colitis in BALB/c mice,” *Oxidative Medicine and Cellular Longevity*, vol. 2015, Article ID 605208, 13 pages, 2015.

[32] S. Sánchez-Fidalgo, I. Villegas, A. Cárdeno et al., “Extra-virgin olive oil-enriched diet modulates DSS-colitis-associated colon carcinogenesis in mice,” *Clinical Nutrition*, vol. 29, no. 5, pp. 663–673, 2010.

[33] D. W. Wray, A. Uberoi, L. Lawrenson, D. M. Bailey, and R. S. Richardson, “Oral antioxidants and cardiovascular health in the exercise-trained and untrained elderly: a radically different outcome,” *Clinical Science*, vol. 116, no. 5, pp. 433–441, 2009.

[34] A. M. McNeilly, G. W. Davison, M. H. Murphy et al., “Effect of α-lipoic acid and exercise training on cardiovascular disease risk in obesity with impaired glucose tolerance,” *Lipids in Health and Disease*, vol. 10, no. 1, pp. 217–226, 2011.

[35] A. Showkat, W. R. Bastnagel, and J. Q. Hudson, “Effect of α-lipoic acid on oxidative stress in end-stage renal disease patients receiving intravenous iron,” *International Scholarly Research Notices: Nephrology*, vol. 2014, Article ID 634515, 7 pages, 2014.

[36] R. Brigelius-Flohe and M. Maiorino, “Glutathione peroxidases,” *Biochimica et Biophysica Acta (BBA)—General Subjects*, vol. 1830, no. 5, pp. 3289–3303, 2013.

[37] H. J. Forman, O. Augusto, R. Brigelius-Flohe et al., “Even free radicals should follow some rules: a Guide to free radical research terminology and methodology,” *Free Radical Biology and Medicine*, vol. 78, pp. 233–253, 2016.

[38] T. Akman, M. Akarsu, H. Akpinar, H. Resmi, and E. Sezer, “Erythrocyte deformability and oxidative stress in inflammatory bowel disease,” *Diseases and Sciences*, vol. 57, no. 2, pp. 458–464, 2012.

[39] A. A. Te Velde, I. Pronk, F. de Kort, and P. C. F. Stokkers, “Glutathione peroxidase 2 and aquaporin 8 as new markers for colonic inflammation in experimental colitis and inflammatory bowel diseases: an important role for H₂O₂?” *European Journal of Gastroenterology and Hepatology*, vol. 20, no. 6, pp. 555–560, 2008.

[40] S. Singh, A. R. Khan, and A. K. Gupta, “Role of glutathione in cancer pathophysiology and therapeutic interventions,” *Journal of Experimental Therapeutics and Oncology*, vol. 9, no. 4, pp. 303–316, 2012.

[41] J. Pravda, “Radical induction theory of ulcerative colitis,” *World Journal of Gastroenterology*, vol. 11, no. 16, pp. 2371–2384, 2005.

[42] P. Rutgeerts, S. Vermeire, and G. Van Assche, “Biological therapies for inflammatory bowel diseases,” *Gastroenterology*, vol. 136, no. 4, pp. 1182–1197, 2009.

[43] G. Bisping, N. Lügering, S. Lütke-Brinstrup et al., “Patients with inflammatory bowel disease (IBD) reveal increased induction capacity of intracellular interferon-gamma (IFN-γ) in peripheral CD8+ lymphocytes co-cultured with intestinal epithelial cells,” *Clinical and Experimental Immunology*, vol. 123, no. 1, pp. 15–22, 2001.

[44] S. Hoves, S. W. Krause, C. Schütz et al., “Monocyte-derived macrophages mediate anergy in allogeneic T cells and induce regulatory T cells,” *The Journal of Immunology*, vol. 177, no. 4, pp. 2691–2698, 2006.
[45] L. G. Guijarro, J. Mate, J. P. Gisbert et al., “N-acetyl-L-cysteine combined with mesalazine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study,” *World Journal of Gastroenterology*, vol. 14, no. 18, pp. 2851–2857, 2008.

[46] B. M. Fournier and C. A. Parkos, “The role of neutrophils during intestinal inflammation,” *Mucosal Immunology*, vol. 5, no. 4, pp. 354–366, 2012.

[47] X.-M. Yu and X.-F. Wang, “The in vitro proliferation and cytokine production of Vα24+Vβ11+ natural killer T cells in patients with systemic lupus erythematosus,” *Chinese Medical Journal*, vol. 124, no. 1, pp. 61–65, 2011.

[48] G. Bamiás, G. Kaltsa, and S. D. Ladas, “Cytokines in the pathogenesis of ulcerative colitis,” *Discovery Medicine*, vol. 11, no. 60, pp. 459–467, 2011.

[49] Y. You, J.-J. Fu, J. Meng, G.-D. Huang, and Y.-H. Liu, “Effect of N-acetylcysteine on the murine model of colitis induced by dextran sodium sulfate through up-regulating PON1 activity,” *Digestive Diseases and Sciences*, vol. 54, no. 8, pp. 1643–1650, 2009.

[50] P. P. Trivedi and G. B. Jena, “Role of α-lipoic acid in dextran sulfate sodium-induced ulcerative colitis in mice: studies on inflammation, oxidative stress, DNA damage and fibrosis,” *Food and Chemical Toxicology*, vol. 59, pp. 339–355, 2013.

[51] K. Karmiris, A. Avgerinos, A. Tavernaraki et al., “Prevalence and characteristics of extra-intestinal manifestations in a large cohort of greek patients with inflammatory bowel disease,” *Journal of Crohn’s and Colitis*, vol. 10, no. 4, pp. 429–436, 2016.

[52] E. Gizard, A. C. Ford, J.-P. Bronowicki, and L. Peyrin-Biroulet, “Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease,” *Alimentary Pharmacology & Therapeutics*, vol. 40, no. 1, pp. 3–15, 2014.

[53] W. F. Balistreri, “Hepatobiliary complications of inflammatory bowel disease: overview of the issues,” *Inflammatory Bowel Diseases*, vol. 4, no. 3, pp. 220–224, 1998.

[54] D. R. Lichtenstein, “Hepatobiliary complications of inflammatory bowel disease,” *Current Gastroenterology Reports*, vol. 13, no. 5, pp. 495–505, 2011.

[55] P. G. K. Venkatesh, U. Navaneethan, and B. Shen, “Hepatobiliary disorders and complications of inflammatory bowel disease,” *Journal of Digestive Diseases*, vol. 12, no. 4, pp. 245–256, 2011.

[56] Y.-H. Paik, J. Kim, T. Aoyama, S. De Minicis, R. Bataller, and D. A. Brenner, “Role of NADPH oxidases in liver fibrosis,” *Antioxidants & Redox Signaling*, vol. 20, no. 17, pp. 2854–2872, 2014.

[57] E. G. Giannini, R. Testa, and V. Savarino, “Liver enzyme alteration: a guide for clinicians,” *Canadian Medical Association Journal*, vol. 172, no. 3, pp. 367–379, 2005.